Qrons Inc.

Equities

QRON

US74737F1012

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:25:39 08/03/2024 pm IST			5-day change	1st Jan Change
0.1855 ^USD	-11.68%		-.--%	-19.35%

15/05	Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/04	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

March 30, 2020 at 08:35 pm IST

Qrons Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 1.516 million compared to USD 3.904 million a year ago. Net loss was USD 1.546 million compared to USD 3.931 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.31 a year ago.

Latest news about Qrons Inc.

Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Qrons Inc. Announces the Filing of A Provisional Patent Application in Furtherance of Its Neuronal and Infectious Disease Treatments Development, Including Sepsis	14/23/14	CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
Qrons Files U.S. National Phase of Its Patent Application in Furtherance of Its Qs200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels	22/23/22	CI
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis	14/22/14	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	11/22/11	CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt	11/22/11	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	16/21/16	CI
Qrons Inc. announced that it has received $0.115 million in funding from Quick Capital, LLC	15/21/15	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	01/21/01	CI
Qrons Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	17/20/17	CI
Qrons Inc. announced that it has received $0.1 million in funding	23/20/23	CI
Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	15/20/15	CI
Qrons Inc. announced a financing transaction	11/20/11	CI
Qrons Inc. cancelled the transaction announced on May 21, 2019	21/20/21	CI

Chart Qrons Inc.

Duration

Period

More charts

Company Profile

Qrons Inc. is a biotechnology company. The Company is focuses on developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria. It has developed a treatment that integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable implant, smart materials, and a novel delivery system. The Company has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries (TBIs), both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company researches in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QRONS INC.	-19.35%	2.53M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research